Related Experiment Video
Updated: Aug 9, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Prospects for the prevention of stroke
1Sahlgrenska University Hospital/Ostra, Göteborg, Sweden. bdahlof@scri.se
Insights
Angiotensin II receptor blockers (ARBs) offer stroke prevention benefits beyond blood pressure control. Studies like LIFE and MOSES show ARBs reduce stroke incidence, LVH, and other conditions, with telmisartan showing promise.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Stroke represents a significant epidemic, necessitating novel treatment strategies.
- Blood pressure control is crucial, but specific antihypertensive therapies, such as renin-angiotensin system blockers, are also vital.
- Left ventricular hypertrophy (LVH) is a common comorbidity in hypertensive patients.
Purpose of the Study:
- To evaluate the benefits of angiotensin II receptor blockers (ARBs) beyond blood pressure reduction in hypertension management.
- To assess the efficacy of ARBs in preventing stroke and other cardiovascular events.
- To explore the potential of specific ARBs, like telmisartan, in stroke prevention.
Main Methods:
- Review of clinical trial data, including the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, Study on COgnition and Prognosis in the Elderly (SCOPE), and MOrbidity and mortality after Stroke, Eprosartan compared with nitrendipine in Secondary prevention (MOSES) trial.
- Analysis of experimental findings and clinical evidence supporting ARB benefits in stroke prevention.
- Consideration of telmisartan's pharmacological profile, including its 24-hour efficacy and peroxisome proliferator-activated receptor-gamma activity.
Main Results:
- The LIFE study demonstrated that losartan-based therapy led to LVH regression and significantly reduced stroke incidence, new-onset diabetes, and atrial fibrillation compared to atenolol.
- The MOSES trial indicated clear benefits of ARBs independent of blood pressure lowering in secondary stroke prevention.
- Evidence suggests ARBs provide advantages beyond mere blood pressure reduction.
Conclusions:
- ARBs represent a valuable therapeutic class for stroke prevention, offering benefits beyond blood pressure control.
- Specific ARBs, such as telmisartan, possess unique properties that may enhance stroke prevention, particularly in secondary prevention settings.
- Further research, like the PRoFESS study, is investigating the role of agents like telmisartan in preventing recurrent strokes.
Abstract:
We are currently fighting a battle against a stroke epidemic. Implementation of new treatment strategies could save many patients in the future. The control of blood pressure is a major objective; however, choosing specific antihypertensive therapy (e.g. an agent blocking the renin-angiotensin system) is also important. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study demonstrates potential benefits beyond blood pressure reduction of prescribing an angiotensin II receptor blocker (ARB) compared with more established therapy in patients with left ventricular hypertrophy (LVH). Losartan-based therapy brought about regression of LVH and reduced incidences of fatal and non-fatal stroke by 25%, new-onset diabetes by 25% and atrial fibrillation by 30% more than atenolol-based therapy for a similar blood pressure control and better tolerability. The Study on COgnition and Prognosis in the Elderly (SCOPE) study, although difficult to interpret, does not contradict an ARB benefit beyond blood pressure lowering in primary prevention linked to targeting the angiotensin type 1 receptor. The findings of the MOrbidity and mortality after Stroke, Eprosartan compared with nitrendipine in Secondary prevention (MOSES) trial suggest clear-cut ARB benefits independent of blood pressure lowering in secondary stroke prevention. Experimental findings and other clinical evidence further support the benefits of ARBs in stroke prevention. Telmisartan is an ARB with a particularly interesting profile for stroke; given the 24-hour efficacy with more pronounced protection against the morning blood pressure surge and peroxisome proliferator-activated receptor-gamma activity at clinical doses. The unique properties of telmisartan for secondary stroke prevention are being tested in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) study.
Related Concept Videos
Ischemic Stroke l: Introduction
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Ischemic Stroke ll: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Hemorrhagic Stroke l: Introduction
Stroke: Introduction and Types